▶ 調査レポート

世界の間葉系幹細胞(MSC)市場2022年-2032年:コンポーネント別(製品(ワークフロータイプ、製品タイプ)、サービス)、種類別(自家培養、同種培養)、分離元別(骨髄、臍帯血、末梢血、卵管、胎児肝、肺、脂肪組織)、疾患別(骨&軟骨修復、循環器疾患、炎症&免疫疾患、肝疾患、がん、GvHD、その他)

• 英文タイトル:Mesenchymal Stem Cells Market by Component (Product (Workflow Type and Product Type) and Service), By Type (Autologous and Allogenic), By Source of Isolation (Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung and Adipose Tissues), By Indication (into Bone and Cartilage Repair, Cardiovascular Disease, Inflammatory and Immunological Diseases, Liver Diseases, Cancer, GvHD and Other Indications) and by Region - 2022 to 2032

Transparency Market Researchが調査・発行した産業分析レポートです。世界の間葉系幹細胞(MSC)市場2022年-2032年:コンポーネント別(製品(ワークフロータイプ、製品タイプ)、サービス)、種類別(自家培養、同種培養)、分離元別(骨髄、臍帯血、末梢血、卵管、胎児肝、肺、脂肪組織)、疾患別(骨&軟骨修復、循環器疾患、炎症&免疫疾患、肝疾患、がん、GvHD、その他) / Mesenchymal Stem Cells Market by Component (Product (Workflow Type and Product Type) and Service), By Type (Autologous and Allogenic), By Source of Isolation (Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung and Adipose Tissues), By Indication (into Bone and Cartilage Repair, Cardiovascular Disease, Inflammatory and Immunological Diseases, Liver Diseases, Cancer, GvHD and Other Indications) and by Region - 2022 to 2032 / TMRGL26735資料のイメージです。• レポートコード:TMRGL26735
• 出版社/出版日:Transparency Market Research / 2022年11月16日
• レポート形態:英文、PDF、250ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥869,250 (USD5,795)▷ お問い合わせ
  Multi User¥1,319,250 (USD8,795)▷ お問い合わせ
  Corporate License¥1,769,250 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
※当レポートは英文です。下記の日本語概要・目次は自動翻訳を利用し作成されました。正確な概要・目次はお問い合わせフォームからサンプルを請求してご確認ください。

2017年から2021年までの間葉系幹細胞(MSC)の販売分析 Vs 2022年から2032年までの市場展望

間葉系幹細胞(MSC)の世界市場は、2017~2021年の期間にCAGR14.7%で拡大しました。また、2032年末までにCAGR17.3%で躍進し、164億米ドルの売上を記録すると予測されています。

なぜ間葉系幹細胞(MSC)市場は急成長しているのか?

間葉系幹細胞(MSC)は、自己再生能力を持ち、多系統の分化を示すストローマ細胞で、その重要性や用途を分析する研究や調査が増えるにつれ、人気が高まっています。間葉系幹細胞は、臍帯、骨髄、脂肪組織など、さまざまな分離源から得られます。月経血や子宮内膜のようなソースからこれらの細胞が発見されたこともある。ヒトMSCは入手しやすく、大量に採取することも比較的容易であり、培養も可能である。また、免疫抑制性、自己複製性、抗炎症性などの特徴を持つことから、広く利用されています。
MSCの使用に関する研究と応用の拡大、およびこの研究のための資金の大幅な増加は、市場の主要な推進要因になると予想されます。ARDSなどのCOVID-19合併症の治療におけるMSCの可能性は、研究を増加させ、したがってその需要も増加しています。さらに、メーカーは、試験の成功による潜在的な需要を満たすために、MSCの商業グレードの生産のための技術の向上を検討しています。

地域別インサイト

北米は間葉系幹細胞(MSC)の需要にどのように貢献しているのでしょうか?

北米はMSCの需要に大きく寄与しており、米国だけで市場需要の45%以上を占めています。特にCOVID-19の治療への応用において、多数の主要企業の立地と集中的な資金調達の増加が需要に影響を与えています。
2020年4月、カナダ政府が支援するカナダの幹細胞ネットワークは、COVID-19に関連する3つのプロジェクトへの資金提供を発表しました。そのうちの1つ「COVID-19誘発急性呼吸窮迫症候群に対する細胞免疫療法:CIRCA-19試験」は、COVID-19患者に認められる急性呼吸窮迫に対する治療法としてMSCを使用するための臨床試験を実施するために30万米ドルを獲得したものです。
2022年6月には、資金調達コンペの結果、様々なプロジェクトに22.4Mn米ドルを配分したことを発表しました。敗血症性ショックに対する細胞性免疫療法としての臍帯間葉系幹細胞の使用に関する研究は、第II相RCTのために999,850米ドルが授与されました。
2021年10月、FDAは、希少疾患のケアのためのpf医薬品の支援のため、11種類の臨床試験に対して25百万米ドルの資金提供を発表しました。そのうちの1つは、メイヨークリニック・ロチェスターの「多系統萎縮症の治療のための自己間葉系幹細胞の髄腔内投与」研究のフェーズ2であった。

国別インサイト

中国間葉系幹細胞(MSC)市場の分析

中国は、世界の間葉系幹細胞(MSC)の中で2番目に大きな市場であり、市場規模は23億米ドル、2022年から2032年の間にCAGR22.7%で成長すると予測され、20億米ドルの絶対額の機会を記録しています。
幹細胞研究に対する大規模な中央支援と質の高い研究センターの存在が、成長の主な理由です。中国国家自然科学基金によると、1997年から2019年の間に、5億7600万米ドルの資金が幹細胞プログラムに授与されました。

米国の間葉系幹細胞(MSC)市場の分析

米国は、間葉系幹細胞(MSC)の最大の市場となることが予想されます。米国の間葉系幹細胞市場は、2022年〜2032年の間にCAGR17.4%で成長し、2032年には76億米ドルの市場規模に達すると予測されます。2022年から2032年にかけての市場の絶対額は61億米ドルに達すると予想されています。

英国間葉系幹細胞(MSC)市場の分析

英国の間葉系幹細胞(MSC)市場は、2022年〜2032年の間にCAGR19.5%で成長し、6億4360万米ドルの評価額に達すると予測されます。同国の市場は、534.7Mnドルの絶対的なドル機会を総計すると予想されます。

韓国の間葉系幹細胞(MSC)市場の分析

韓国の間葉系幹細胞(MSC)市場は、2032年までに276Mnの市場規模を記録すると予測されます。同市場は2022年から2032年の間に、CAGR16%を記録しながら214Mnドルの絶対的な機会利益を生み出すと予測されています。

カテゴリー別インサイト

どのタイプの間葉系幹細胞(MSC)が市場の需要を牽引しているのでしょうか?

CAGR14.3%を記録し、今後10年間のCAGRが14.7%と予測されている同種移植幹細胞が、間葉系幹細胞(MSC)のトップタイプであると言えます。自家用MSCは、細胞に対する免疫反応がないため安全な選択肢であるが、いくつかの制約があります。
特に、高齢者や合併症のある患者さんが多いため、必要な量を確保することが難しい、あるいは不可能な場合があり、得られたMSCも効率が悪い可能性が高く、また、抽出と膨張のプロセスには時間がかかるため、緊急時の応用には限界があります。一方、同種幹細胞は、事前にスクリーニングされたドナーから得られ、大規模に製造され、緊急事態に必要な分析および使用が可能です。

レポート目次

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. Value Chain Analysis

3.5.1. Profit Margin Analysis

3.5.2. Service Providers

3.6. PESTLE and Porter’s Analysis

3.7. Regulatory Landscape

3.7.1. By Key Regions

3.7.2. By Key Countries

3.8. Regional Parent Market Outlook

4. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast, 2022-2032

4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021

4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Component

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Bn) Analysis By Component, 2017-2021

5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Component, 2022-2032

5.3.1. Product

5.3.1.1. Workflow Type

5.3.1.2. Product Type

5.3.2. Service

5.4. Y-o-Y Growth Trend Analysis By Component, 2017-2021

5.5. Absolute $ Opportunity Analysis By Component, 2022-2032

6. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Type

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Bn) Analysis By Type, 2017-2021

6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Type, 2022-2032

6.3.1. Autologous

6.3.2. Allogeneic

6.4. Y-o-Y Growth Trend Analysis By Type, 2017-2021

6.5. Absolute $ Opportunity Analysis By Type, 2022-2032

7. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Source of Isolation

7.1. Introduction / Key Findings

7.2. Historical Market Size Value (US$ Bn) Analysis By Source of Isolation, 2017-2021

7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Source of Isolation, 2022-2032

7.3.1. Bone Marrow

7.3.2. Cord Blood

7.3.3. Peripheral Blood

7.3.4. Fallopian Tube

7.3.5. Fetal Liver

7.3.6. Lung

7.3.7. Adipose Tissues

7.4. Y-o-Y Growth Trend Analysis By Source of Isolation, 2017-2021

7.5. Absolute $ Opportunity Analysis By Source of Isolation, 2022-2032

8. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Indication

8.1. Introduction / Key Findings

8.2. Historical Market Size Value (US$ Bn) Analysis By Indication , 2017-2021

8.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Indication , 2022-2032

8.3.1. Bone And Cartilage Repair

8.3.2. Cardiovascular Disease

8.3.3. Inflammatory And Immunological Diseases

8.3.4. Liver Diseases

8.3.5. Cancer

8.3.6. GvHD

8.3.7. Other Indications

8.4. Y-o-Y Growth Trend Analysis By Indication , 2017-2021

8.5. Absolute $ Opportunity Analysis By Indication , 2022-2032

9. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Region

9.1. Introduction

9.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021

9.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032

9.3.1. North America

9.3.2. Latin America

9.3.3. Europe

9.3.4. Asia Pacific

9.3.5. MEA

9.4. Market Attractiveness Analysis By Region

10. North America Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country

10.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

10.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

10.2.1. By Country

10.2.1.1. Value (US$ Bn)ed States

10.2.1.2. Canada

10.2.2. By Component

10.2.3. By Type

10.2.4. By Source of Isolation

10.2.5. By Indication

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Component

10.3.3. By Type

10.3.4. By Source of Isolation

10.3.5. By Indication

10.4. Key Takeaways

11. Latin America Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country

11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

11.2.1. By Country

11.2.1.1. Brazil

11.2.1.2. Mexico

11.2.1.3. Rest of Latin America

11.2.2. By Component

11.2.3. By Type

11.2.4. By Source of Isolation

11.2.5. By Indication

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Component

11.3.3. By Type

11.3.4. By Source of Isolation

11.3.5. By Indication

11.4. Key Takeaways

12. Europe Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country

12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

12.2.1. By Country

12.2.1.1. Germany

12.2.1.2. U.K.

12.2.1.3. France

12.2.1.4. Spain

12.2.1.5. Italy

12.2.1.6. Russia

12.2.1.7. Rest of Europe

12.2.2. By Component

12.2.3. By Type

12.2.4. By Source of Isolation

12.2.5. By Indication

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Component

12.3.3. By Type

12.3.4. By Source of Isolation

12.3.5. By Indication

12.4. Key Takeaways

13. Asia Pacific Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country

13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

13.2.1. By Country

13.2.1.1. China

13.2.1.2. Japan

13.2.1.3. India

13.2.1.4. South Korea

13.2.1.5. Australia

13.2.1.6. Rest of APAC

13.2.2. By Component

13.2.3. By Type

13.2.4. By Source of Isolation

13.2.5. By Indication

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Component

13.3.3. By Type

13.3.4. By Source of Isolation

13.3.5. By Indication

13.4. Key Takeaways

14. MEA Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country

14.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

14.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

14.2.1. By Country

14.2.1.1. South Africa

14.2.1.2. Saudi Arabia

14.2.1.3. UAE

14.2.1.4. Israel

14.2.1.5. Rest of MEA

14.2.2. By Component

14.2.3. By Type

14.2.4. By Source of Isolation

14.2.5. By Indication

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Component

14.3.3. By Type

14.3.4. By Source of Isolation

14.3.5. By Indication

14.4. Key Takeaways

15. Key Countries Mesenchymal Stem Cells Market Analysis

15.1. Value (US$ Bn)ed States

15.1.1. Pricing Analysis

15.1.2. Market Share Analysis, 2021

15.1.2.1. By Component

15.1.2.2. By Type

15.1.2.3. By Source of Isolation

15.1.2.4. By Indication

15.2. Canada

15.2.1. Pricing Analysis

15.2.2. Market Share Analysis, 2021

15.2.2.1. By Component

15.2.2.2. By Type

15.2.2.3. By Source of Isolation

15.2.2.4. By Indication

15.3. Brazil

15.3.1. Pricing Analysis

15.3.2. Market Share Analysis, 2021

15.3.2.1. By Component

15.3.2.2. By Type

15.3.2.3. By Source of Isolation

15.3.2.4. By Indication

15.4. Mexico

15.4.1. Pricing Analysis

15.4.2. Market Share Analysis, 2021

15.4.2.1. By Component

15.4.2.2. By Type

15.4.2.3. By Source of Isolation

15.4.2.4. By Indication

15.5. Germany

15.5.1. Pricing Analysis

15.5.2. Market Share Analysis, 2021

15.5.2.1. By Component

15.5.2.2. By Type

15.5.2.3. By Source of Isolation

15.5.2.4. By Indication

15.6. U.K.

15.6.1. Pricing Analysis

15.6.2. Market Share Analysis, 2021

15.6.2.1. By Component

15.6.2.2. By Type

15.6.2.3. By Source of Isolation

15.6.2.4. By Indication

15.7. France

15.7.1. Pricing Analysis

15.7.2. Market Share Analysis, 2021

15.7.2.1. By Component

15.7.2.2. By Type

15.7.2.3. By Source of Isolation

15.7.2.4. By Indication

15.8. Spain

15.8.1. Pricing Analysis

15.8.2. Market Share Analysis, 2021

15.8.2.1. By Component

15.8.2.2. By Type

15.8.2.3. By Source of Isolation

15.8.2.4. By Indication

15.9. Italy

15.9.1. Pricing Analysis

15.9.2. Market Share Analysis, 2021

15.9.2.1. By Component

15.9.2.2. By Type

15.9.2.3. By Source of Isolation

15.9.2.4. By Indication

15.10. Russia

15.10.1. Pricing Analysis

15.10.2. Market Share Analysis, 2021

15.10.2.1. By Component

15.10.2.2. By Type

15.10.2.3. By Source of Isolation

15.10.2.4. By Indication

15.11. China

15.11.1. Pricing Analysis

15.11.2. Market Share Analysis, 2021

15.11.2.1. By Component

15.11.2.2. By Type

15.11.2.3. By Source of Isolation

15.11.2.4. By Indication

15.12. Japan

15.12.1. Pricing Analysis

15.12.2. Market Share Analysis, 2021

15.12.2.1. By Component

15.12.2.2. By Type

15.12.2.3. By Source of Isolation

15.12.2.4. By Indication

15.13. India

15.13.1. Pricing Analysis

15.13.2. Market Share Analysis, 2021

15.13.2.1. By Component

15.13.2.2. By Type

15.13.2.3. By Source of Isolation

15.13.2.4. By Indication

15.14. South Korea

15.14.1. Pricing Analysis

15.14.2. Market Share Analysis, 2021

15.14.2.1. By Component

15.14.2.2. By Type

15.14.2.3. By Source of Isolation

15.14.2.4. By Indication

15.15. Australia

15.15.1. Pricing Analysis

15.15.2. Market Share Analysis, 2021

15.15.2.1. By Component

15.15.2.2. By Type

15.15.2.3. By Source of Isolation

15.15.2.4. By Indication

15.16. South Africa

15.16.1. Pricing Analysis

15.16.2. Market Share Analysis, 2021

15.16.2.1. By Component

15.16.2.2. By Type

15.16.2.3. By Source of Isolation

15.16.2.4. By Indication

15.17. Saudi Arabia

15.17.1. Pricing Analysis

15.17.2. Market Share Analysis, 2021

15.17.2.1. By Component

15.17.2.2. By Type

15.17.2.3. By Source of Isolation

15.17.2.4. By Indication

15.18. UAE

15.18.1. Pricing Analysis

15.18.2. Market Share Analysis, 2021

15.18.2.1. By Component

15.18.2.2. By Type

15.18.2.3. By Source of Isolation

15.18.2.4. By Indication

15.19. Israel

15.19.1. Pricing Analysis

15.19.2. Market Share Analysis, 2021

15.19.2.1. By Component

15.19.2.2. By Type

15.19.2.3. By Source of Isolation

15.19.2.4. By Indication

16. Market Structure Analysis

16.1. Competition Dashboard

16.2. Competition Benchmarking

16.3. Market Share Analysis of Top Players

16.3.1. By Regional

16.3.2. By Component

16.3.3. By Type

16.3.4. By Source of Isolation

16.3.5. By Indication

17. Competition Analysis

17.1. Competition Deep Dive

17.1.1. Thermo Fisher Scientific

17.1.1.1. Overview

17.1.1.2. Product Portfolio

17.1.1.3. Profitability by Market Segments

17.1.1.4. Sales Footprint

17.1.1.5. Strategy Overview

17.1.1.5.1. Marketing Strategy

17.1.1.5.2. Product Strategy

17.1.1.5.3. Channel Strategy

17.1.2. Cell Applications, Inc.

17.1.2.1. Overview

17.1.2.2. Product Portfolio

17.1.2.3. Profitability by Market Segments

17.1.2.4. Sales Footprint

17.1.2.5. Strategy Overview

17.1.2.5.1. Marketing Strategy

17.1.2.5.2. Product Strategy

17.1.2.5.3. Channel Strategy

17.1.3. Cyagen Biosciences

17.1.3.1. Overview

17.1.3.2. Product Portfolio

17.1.3.3. Profitability by Market Segments

17.1.3.4. Sales Footprint

17.1.3.5. Strategy Overview

17.1.3.5.1. Marketing Strategy

17.1.3.5.2. Product Strategy

17.1.3.5.3. Channel Strategy

17.1.4. Axol Biosciences Ltd.

17.1.4.1. Overview

17.1.4.2. Product Portfolio

17.1.4.3. Profitability by Market Segments

17.1.4.4. Sales Footprint

17.1.4.5. Strategy Overview

17.1.4.5.1. Marketing Strategy

17.1.4.5.2. Product Strategy

17.1.4.5.3. Channel Strategy

17.1.5. Cytori Therapeutics Inc.

17.1.5.1. Overview

17.1.5.2. Product Portfolio

17.1.5.3. Profitability by Market Segments

17.1.5.4. Sales Footprint

17.1.5.5. Strategy Overview

17.1.5.5.1. Marketing Strategy

17.1.5.5.2. Product Strategy

17.1.5.5.3. Channel Strategy

17.1.6. Stemcell Technologies Inc

17.1.6.1. Overview

17.1.6.2. Product Portfolio

17.1.6.3. Profitability by Market Segments

17.1.6.4. Sales Footprint

17.1.6.5. Strategy Overview

17.1.6.5.1. Marketing Strategy

17.1.6.5.2. Product Strategy

17.1.6.5.3. Channel Strategy

17.1.7. Celprogen Inc

17.1.7.1. Overview

17.1.7.2. Product Portfolio

17.1.7.3. Profitability by Market Segments

17.1.7.4. Sales Footprint

17.1.7.5. Strategy Overview

17.1.7.5.1. Marketing Strategy

17.1.7.5.2. Product Strategy

17.1.7.5.3. Channel Strategy

17.1.8. Brainstorm Cell Therapeutics Inc

17.1.8.1. Overview

17.1.8.2. Product Portfolio

17.1.8.3. Profitability by Market Segments

17.1.8.4. Sales Footprint

17.1.8.5. Strategy Overview

17.1.8.5.1. Marketing Strategy

17.1.8.5.2. Product Strategy

17.1.8.5.3. Channel Strategy

17.1.9. Stemedica Cell Technologies, Inc.

17.1.9.1. Overview

17.1.9.2. Product Portfolio

17.1.9.3. Profitability by Market Segments

17.1.9.4. Sales Footprint

17.1.9.5. Strategy Overview

17.1.9.5.1. Marketing Strategy

17.1.9.5.2. Product Strategy

17.1.9.5.3. Channel Strategy

17.1.10. Merck Millipore

17.1.10.1. Overview

17.1.10.2. Product Portfolio

17.1.10.3. Profitability by Market Segments

17.1.10.4. Sales Footprint

17.1.10.5. Strategy Overview

17.1.10.5.1. Marketing Strategy

17.1.10.5.2. Product Strategy

17.1.10.5.3. Channel Strategy

17.1.11. Smith & Nephew

17.1.11.1. Overview

17.1.11.2. Product Portfolio

17.1.11.3. Profitability by Market Segments

17.1.11.4. Sales Footprint

17.1.11.5. Strategy Overview

17.1.11.5.1. Marketing Strategy

17.1.11.5.2. Product Strategy

17.1.11.5.3. Channel Strategy

17.1.12. Lonza AG

17.1.12.1. Overview

17.1.12.2. Product Portfolio

17.1.12.3. Profitability by Market Segments

17.1.12.4. Sales Footprint

17.1.12.5. Strategy Overview

17.1.12.5.1. Marketing Strategy

17.1.12.5.2. Product Strategy

17.1.12.5.3. Channel Strategy

17.1.13. PromoCell GMBH

17.1.13.1. Overview

17.1.13.2. Product Portfolio

17.1.13.3. Profitability by Market Segments

17.1.13.4. Sales Footprint

17.1.13.5. Strategy Overview

17.1.13.5.1. Marketing Strategy

17.1.13.5.2. Product Strategy

17.1.13.5.3. Channel Strategy

17.1.14. Sciencell Research Laboratories

17.1.14.1. Overview

17.1.14.2. Product Portfolio

17.1.14.3. Profitability by Market Segments

17.1.14.4. Sales Footprint

17.1.14.5. Strategy Overview

17.1.14.5.1. Marketing Strategy

17.1.14.5.2. Product Strategy

17.1.14.5.3. Channel Strategy

17.1.15. American Type Culture Collection

17.1.15.1. Overview

17.1.15.2. Product Portfolio

17.1.15.3. Profitability by Market Segments

17.1.15.4. Sales Footprint

17.1.15.5. Strategy Overview

17.1.15.5.1. Marketing Strategy

17.1.15.5.2. Product Strategy

17.1.15.5.3. Channel Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

List of Tables

Table 1: Global Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Region, 2017-2032

Table 2: Global Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032

Table 3: Global Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032

Table 4: Global Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032

Table 5: Global Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032

Table 6: North America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 7: North America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032

Table 8: North America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032

Table 9: North America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032

Table 10: North America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032

Table 11: Latin America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 12: Latin America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032

Table 13: Latin America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032

Table 14: Latin America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032

Table 15: Latin America Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032

Table 16: Europe Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 17: Europe Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032

Table 18: Europe Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032

Table 19: Europe Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032

Table 20: Europe Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032

Table 21: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 22: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032

Table 23: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032

Table 24: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032

Table 25: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032

Table 26: MEA Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Country, 2017-2032

Table 27: MEA Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Component, 2017-2032

Table 28: MEA Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Type, 2017-2032

Table 29: MEA Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Source of Isolation, 2017-2032

Table 30: MEA Mesenchymal Stem Cells Market Value (US$ Bn) Forecast by Indication , 2017-2032